Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMBINE: Elacestrant plus exemestane in pretreated HR+/HER2- metastatic breast cancer with FES-avid disease
2024-519792-25-00Phase 2Authorised
- Sponsor
- European Institute of Oncology
- Start
- Oct 2025
- Modality
- Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of elacestrant and exemestane in breast cancer, sponsored by European Institute of Oncology. Primary endpoint: 6-month progression-free survival rate per RECIST v1.1. Planned start Oct 2025; status: authorised.
02
Drugs
elacestrantexemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-519792-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519792-25-00.